NCT06776432 - Safety and Efficacy Study of Sivopixant, Acetazolamide and SASS-001 in Sleep Apnea | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 2, 2025

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Sleep Apnea

Interventions

DRUG

Sivopixant

Administered as specified in the treatment arm

DRUG

Placebo

Administered as specified in the treatment arm.

DRUG

Acetazolamide

Administered as specified in the treatment arm

DRUG

SASS-001

Administered as specified in the treatment arm

Trial Locations (9)

29732

RECRUITING

OnSite Clinical Solutions, Rock Hill

33176

RECRUITING

PharmaDev Clinical Research Institute, LLC, Miami

33511

RECRUITING

Teradan Clinical Trials, Brandon

45245

RECRUITING

Intrepid Research, LLC, Cincinnati

48201

RECRUITING

John D. Dingell VA Medical Center, Detroit

55905

RECRUITING

Mayo Clinic, Rochester

77340

RECRUITING

Huntsville Research Institute LLC, Huntsville

92037

RECRUITING

Altman Clinical and Translational Research Institute (ACTRI), La Jolla

02747

RECRUITING

Infinity Medical Research, North Dartmouth

All Listed Sponsors

lead

Shionogi Apnimed Sleep Science

INDUSTRY